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Abstract
● AIm: To evaluate the clinical, radiological, and treatment 
features of lacrimal gland tumors.
● methods: Retrospective review of 99 eyes of 92 
patients with lacrimal gland tumors diagnosed and managed 
in a single institution between January 1999 and march 
2017. Clinical and radiological features, histopathology, 
treatment methods, and prognosis were evaluated.
● Results: The mean patient age was 40.3 (range: 7-80)y.
The diagnosis was made histopathologically in 91 (91.9%) 
tumors and on a clinical and radiological basis in 8 (8.1%) 
tumors. Final diagnoses included idiopathic orbital 
inflammation (pseudotumor) in 46 (46.5%) lesions, 
pleomorphic adenoma in 14 (14.1%), adenoid cystic 
carcinoma in 12 (12.1%), granulomatous inflammation in 10 
(10.1%), lymphoma in 5 (5.0%), benign reactive lymphoid 
hyperplasia in 3 (3.0%), dacryops in 3 (3.0%), carcinoma 
ex pleomorphic adenoma in 2 (2.0%), adenocarcinoma in 
1 (1.0%), dermoid cyst in 1 (1.0%), cavernous hemangioma 
in 1 (1.0%), and leukemic infiltration in 1 (1.0%). Non-
epithelial tumors comprised 64.6% (n=64) of all lacrimal 
gland tumors, epithelial tumors 32.3% (n=32), dermoid cyst 
1% (n=1), cavernous hemangioma 1% (n=1), and leukemic 
infiltration 1% (n=1). There were in total 78 (78.8%) benign 
and 21 (21.2%) malignant tumors. 
● ConClusIon: overall, 65% of lacrimal gland tumors were 
of non-epithelial origin and 32% of epithelial origin. By his-
topathology and clinical evaluation, 79% of lacrimal gland 
tumors were benign. The most common lacrimal gland 
tumors include idiopathic orbital inflammation (46.5%), 
epithelial (32.3%), and lymphoproliferative (8.1%) lesions.
● KeyWoRds: orbit; lacrimal gland; tumor; inflammation; 
epithelial tumor; non-epithelial tumor
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INTRODUCTION
L acrimal gland tumors (LGTs) are uncommon with an estimated incidence of <1/1 000 000 per year[1]. 
LGTs represent 3% to 18% of all orbital tumors[2-5]. There 
may be differences in the distribution of LGTs in different 
countries depending on geographical region, whether clinical 
or histopathological diagnosis is used, characteristics of the 
reporting institution, and patient referral patterns[1,5-6]. Lesions 
of the lacrimal gland can be divided into epithelial and non-
epithelial lesions. Approximately 55%-80% of the LGTs are of 
non-epithelial origin and 20%-45% are of epithelial origin[2-5,7]. 
Non-epithelial masses include non-granulomatous and 
granulomatous inflammation and lymphoproliferative lesions. 
Benign epithelial tumors constitute about half of epithelial 
tumors. Malignant epithelial tumors comprise the other half 
of epithelial tumors. Benign epithelial tumors include lacrimal 
ductal cyst (dacryops) and pleomorphic adenoma (PA). 
Malignant epithelial tumors include adenoid cystic carcinoma 
(ACC), carcinoma ex pleomorphic adenoma (Ca-ex-PA), de 
novo adenocarcinoma, and other rare entities. Of the malignant 
epithelial tumors, ACC is the most common accounting for 
about 66% of the cases, followed by Ca-ex-PA (18%), de novo 
adenocarcinoma (9%), mucoepidermoid carcinoma (3%), and 
other less common lesions[5]. In this study, we aimed to review 
the clinical, radiological, and treatment features of LGTs from 
an oncology center in Turkey.
SUBJECTS AND METHODS
A retrospective review of 99 eyes of 92 cases with the 
diagnosis of LGT managed on the Ocular Oncology Service 
at Ankara University Faculty of Medicine in Turkey between 
January 1999 and March 2017 was made. Two cases which 
had the histopathologic diagnosis of normal lacrimal gland 
tissue during the study interval were excluded. The study was 
approved by the Institutional Review Board. A signed consent 
form was obtained and kept on file for all patients whose 
clinical and radiologic photographs were used in this study.
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A careful history was taken in each case. Every patient 
underwent complete ophthalmic examination and imaging 
[computed tomography (CT) or magnetic resonance imaging 
(MRI)]. The diagnosis was usually made after orbital biopsy 
and histopathologic examination but in a few cases the 
diagnosis was reached based on clinical and radiological 
findings. Complete blood count, peripheral blood smear, 
chest-abdominal CT, neck ultrasonography, and lately 
18F-fluorodeoxyglucose positron emission tomography 
were used to assess the presence of systemic involvement in 
the cases with lacrimal gland carcinoma and ocular adnexal 
lymphoma (OAL). The medical evaluation was made by 
the medical oncologist and follow-up tests were repeated as 
necessary.
RESULTS
The study included 92 cases with a mean age of 40.3 (range: 
7-80)y. Seven cases had bilateral lesions. Fifty-eight (63.1%) 
were females and 34 (36.9%) were males. Demographic data 
and histopathologic/clinical diagnoses are listed in Table 1. 
The most frequent signs and symptoms were eyelid swelling 
[49 (60.5%) cases] (Figure 1A), proptosis [45 (55.5%) cases], 
and presence of an eyelid mass or lump [16 (19.7%) cases] 
(Figure 2A, Table 2). 
The diagnosis was made histopathologically in 91 (91.9%) 
tumors and on a clinical and radiological basis in 8 (8.1%) 
tumors. The surgical technique used in obtaining biopsy 
from 91 tumors included anterior orbitotomy using upper lid 
skin crease approach in 87 tumors, orbitotomy via Kronlein 
approach in 2 tumors, anterior orbitotomy via conjunctival 
approach in 1 tumor, and exenteration (based on the prior 
histopathologic diagnosis of adenocarcinoma) in 1 tumor. 
During surgery, incisional biopsy was performed in 39 (42.8%) 
lesions, total excisional biopsy in 32 (35.2%), and subtotal 
excisional biopsy in 19 (20.9%). 
Final diagnoses were idiopathic orbital inflammation 
(pseudotumor) in 46 (46.5%) lesions, PA in 14 (14.1%) 
(Figure 2D), ACC in 12 (12.1%) (Figure 4C), granulomatous 
inflammation in 10 (10.1%), lymphoma in 5 (5.0%) 
(Figure 3B), benign reactive lymphoid hyperplasia (BRLH) 
in 3 (3.0%), dacryops in 3 (3.0%), Ca-ex-PA in 2 (2.0%), 
adenocarcinoma in 1 (1.0%), dermoid cyst in 1 (1.0%), 
cavernous hemangioma in 1 (1.0%), and leukemic infiltration 
in 1 (1.0%). Non-epithelial tumors comprised 64.6% (n=64) of 
all LGTs, epithelial tumors 32.3% (n=32), dermoid cyst 1.0% 
(n=1), cavernous hemangioma 1.0% (n=1), and leukemic 
infiltration 1.0% (n=1). There were in total 78 (78.8%) benign 
and 21 (21.2%) malignant tumors. Malignant tumors included 
15 cases of malignant epithelial tumors, 5 cases of lymphomas 
and 1 case of leukemic infiltration. 
Table 1 Demographics and histopathologic/clinical diagnoses in 92 cases with LGTs                                                                                   n (%)
LGTs No. of lesions No. of cases Gender (M/F) Mean age (range, y)
Non-epithelial tumors 64 (64.6) 58 (63.0) 23/35 38.5 (7-80)
Inflammatory lesions (dacryoadenitis) 56 (56.6) 50 (54.3) 19/31 34.9 (7-68)
  Non-granulomatous inflammation 46 (46.5) 43 (46.7) 18/25 35.2 (10-68)
  Granulomatous inflammation 10 (10.1) 7 (7.6) 1/6 32.6 (7-68)
  Non-necrotizing granulamotous inflammation 7 (7.1) 5 (5.4) 0/5 32.0 (7-68)
  Necrotizing granulomatous inflammation 3 (3.0) 2 (2.2) 1/1 34.0 (23-44)
Lymphoproliferative lesions 8 (8.1) 8 (8.7) 5/3 61.1 (30-80)
  Lymphoma 5 (5.0) 5 (5.4) 3/2 68.8 (45-80)
  Benign reactive lymphoid hyperplasia 3 (3.0) 3 (3.3) 2/1 48.3 (30-72)
Epithelial tumors 32 (32.3) 31 (33.7) 10/21 42.2 (13-72)
Benign tumors 17 (17.2) 16 (17.4) 6/10 40.6 (16-70)
  Dacryops 3 (3.0) 2 (2.2) 1/1 28.5 (17, 40)
  Pleomorphic adenoma 14 (14.1) 14 (15.2) 5/9 42.3 (16-70)
Malignant tumors 15 (15.1) 15 (16.3) 4/11 43.8 (13-72)
  Adenoid cystic carcinoma 12 (12.1) 12 (13.0) 3/9 39.2 (13-72)
  Carcinoma ex pleomorphic adenoma 2 (2.0) 2 (2.1) 0/2 59.5 (53, 66)
  Adenocarcinoma 1 (1.0) 1 (1.1) 1/0 69
Others 3 (3.0) 3 (3.3) 1/2 58.3 (41-74)
  Cavernous hemangioma 1 (1.0) 1 (1.1) 0/1 60
  Dermoid cyst 1 (1.0) 1 (1.1) 1/0 74
  Leukemic infiltration (acute myeloid) 1 (1.0) 1 (1.1) 0/1 41
Total 99 92 34/58 40.3 (7-80)
LGTs: Lacrimal gland tumors.
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Of 7 bilateral lesions, 6 were diagnosed as dacryoadenitis 
and 1 as dacryops. Six dacryoadenitis and 2 dacryops lesions 
did not undergo biopsy. Additional treatments for residual/
progressive disease and recurrences included systemic 
corticosteroid treatment in 56 (56.6%) lesions, external beam 
radiotherapy (EBRT) in 23 (23.2%), further eye-sparing 
tumor resection in 7 (7.1%), exenteration in 6 (6.1%), 
immunosuppresive/immunomodulatory treatment in 5 (5.1%), 
and systemic chemotherapy in 3 (3.0%). The preoperative CT 
and MRI findings were correlated with the histopathology 
results. Imaging data from the cases with dacryoadenitis and 
lymphoproliferative lesions demonstrated enlarged lacrimal 
gland with a molded configuration and ill-defined margins 
(Figures 1B, 3A). Inflammatory and lymphoproliferative 
lesions were usually hypointense or isointense on both T1 
and T2-weighted images (Figures 1B, 3A) and demonstrated 
contrast enhancement on MRI.
The cases with benign epithelial tumors demonstrated a 
round-to-oval well-circumscribed orbital mass (Figure 2B). 
Three of 14 cases with PA showed bone thinning (expansion) 
(Figure 2B). The cases with carcinomas demonstrated well-
circumscribed round-to-oval orbital mass without bone 














<20 12 (24.0) - 1 (50.0) 1 (7.1) 2 (13.3) - - - 16 (17.4)
20-40 19 (38.0) 1 (12.5) 1 (50.0) 6 (42.9) 4 (26.7) - - - 31 (33.7)
41-60 15 (30.0) 2 (25.0) - 4 (28.6) 6 (40.0) 1 (100.0) - 1 (100.0) 29 (31.5)
61-80 4 (8.0) 5 (62.5) - 3 (21.4) 3 (20.0) - 1 (100.0) - 16 (17.4)
Duration of symptomsa
<6mo 23 (52.2) 4 (50.0) - 3 (27.3) 8 (61.5) 1 (100.0) 1 (100.0) 1 (100.0) 41 (49.3)
6-12mo 15 (34.1) 4 (50.0) 1 (50.0) 6 (54.5) 3 (23.1) - - - 29 (37.3)
>12mo 6 (13.6) - 1 (50.0) 2 (18.2) 2 (15.4) - - - 11 (13.3)
Signs and symptoms
Eyelid swelling 32 (72.7) 6 (75.0) 2 (100.0) 3 (27.3) 5 (38.5) - - 1 (100.0) 49 (60.5)
Ptosis 4 (9.1) 2 (25.0) - 1 (9.1) - - - - 7 (8.6)
Eyelid mass or lump 8 (18.2) 3 (37.5) - 4 (36.4) 1 (7.7) - - - 16 (19.7)
Inflammatory symptoms 11 (25.0) - - - - - - - 11 (13.6)
Pain 2 (4.5) - - 1 (9.1) 8 (61.5) - - - 10 (12.3)
Proptosis 19 (43.2) 3 (37.5) - 9 (81.8) 11 (84.6) 1 (100.0) 1 (100.0) - 45 (55.5)
LGTs: Lacrimal gland tumors; PA: Pleomorphic adenoma. aBased on 81 cases because of lack of data in the remaining 11 cases.
Figure 1 Non-granulomatous dacryoadenitis  A: A 14 year-old girl 
presented with indolent left eyelid edema of 2mo duration; B: T2-
weighted axial MRI demonstrating dacryoadenitis hypointense with 
respect to the extraocular muscles and cerebral gray matter. The tumor 
displays a molded configuration with ill-defined margins (arrowhead) 
conforming to the shape of the globe (arrow).
Figure 2 Lacrimal gland PA  A: A 70 year-old woman complained 
of 8mo history of painless mass in the left upper eyelid causing the 
left eye to be displaced downwards and medially; B: Coronal orbital 
CT shows displacement and indentation of the globe (arrowhead) 
by the round-to-oval well-circumscribed mass and expansion of the 
lacrimal gland fossa (arrows), with no evidence of destructive erosion 
of neighbouring bone; C: Gross photograph of the totally excised PA 
with an intact pseudocapsule; D: Histopathologic examination shows 
PA with an epithelial component composed of tubular and ductal 
structures surrounded by hyaline-rich stroma (hematoxylin-eosin).
Lacrimal gland tumors
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destruction in 7/15 cases (Figure 4A) and ill-defined tumors 
with bone destruction in 5/15 cases. In 3 cases with carcinoma, 
data on tumor shape was lacking. Epithelial tumors usually 
demonstrated isointensity on T1-weighted images (Figure 
4A), hyperintensity on T2-weighted images and demonstrated 
contrast enhancement on MRI.
At a mean follow-up of 54.8 (range: 1-205)mo, 81 cases were 
alive, 6 cases died from metastasis (5 with ACC and 1 with Ca-
ex-PA) and 5 cases died from nontumor-related causes (2 with 
dacryoadenitis, 1 with adenocarcinoma, 1 with lymphoma, and 
1 with cavernous hemangioma).
Analysis of Histopathological Subgroups 
Inflammatory lesions (dacryoadenitis, 50 cases, 56 lesions) 
Forty-four (88.0%) cases with dacryoadenitis had unilateral 
involvement. Bilateral lacrimal gland involvement was noted 
in only 6 (12.0%) cases. All but one of the cases underwent 
anterior orbitotomy for tissue diagnosis. An incisional biopsy 
was performed in 37 (74.0%) lesions, subtotal excisional 
biopsy in 8 (16%) lesions, and dacryoadenectomy in 5 (10.0%) 
lesions as the initial procedure. 
Forty-six (82.1%) lesions had non-granulomatous and 
10 (17.9%) lesions had granulomatous inflammation. Two 
cases with dacryoadenitis were of the sclerosing type. Seven 
of 10 granulomatous lesions had non-necrotizing and 3 had 
necrotizing inflammation. Ten (17.8%) lesions were classified 
as acute dacryoadenitis (<1mo duration of symptoms) and 46 
(82.2%) lesions as chronic dacryoadenitis (>1mo duration of 
symptoms) (Figure 1A). Systemic features associated with 
non-granulomatous inflammation included systemic vasculitis 
(1 case) and dermatomyositis (1 case). Of the granulomatous 
inflammation cases, 1 had sarcoidosis and 1 had Wegener 
granulomatosis. 
Systemic corticosteroid therapy was administered in all cases 
after diagnosis was made. Other additional treatments for 
progressive disease and recurrences included further tumor 
resection/debulking of the lacrimal gland lesion (4 cases), 
azathioprine (3 cases), cyclosporine+azathioprine (1 case), 
cyclosporine (1 case), and EBRT [3 cases (4 eyes)]. Four cases 
(8.0%) with orbital inflammatory lesions had to be kept on 
continuous low dose immunosuppressive treatment because of 
frequent recurrences. 
Lymphoproliferative lesions (8 cases, 8 lesions)  Of 5 lymphoma 
cases, 4 had extranodal marginal zone lymphoma (ENMZL) 
whereas histopathologic typing could not be made in 1 case. 
Systemic involvement was not detected in any case. Five cases 
underwent orbital EBRT (4 cases with lymphoma and 1 case 
with BRLH). The EBRT dose was 40 Gy for lymphomas and 
30 Gy for BRLH. The remaining lymphoma case had total 
excisional biopsy of the orbital lesion. No additional treatment 
was given in the remaining 3 cases. No recurrence was 
observed in any case.
Dacryops (2 cases, 3 lesions)  One case had unilateral and the 
other case had bilateral involvement. The unilateral case was 
treated with total excision because of the eyelid complications 
of dacryops and the bilateral case was observed.
Pleomorphic adenoma (14 cases, 14 lesions)  Of 14 PA cases, 
13 cases underwent anterior orbitotomy and 1 case Kronlein 
(bone removing) orbitotomy. Ten cases had total excision 
(Figure 2C) and 4 had subtotal excision because breach 
of tumor pseudocapsule was present at surgery. In 3 of 4 
cases in whom subtotal excisional biopsy was performed, 
recurrence occurred at a mean of 95.9 (range: 40-185)mo. All 
recurrences were treated with further tumor excision because 
of the infiltrative nature of the recurrent tumor. Two cases had 
significant residual orbital tumor at the end of follow-up.
Figure 3 Lacrimal gland lymphoma in a 75 year-old man  A: 
T1-weighted coronal MRI shows that the lacrimal gland mass has a 
molded appearance (arrowhead) with ill-defined margins (arrows) and 
is isointense with respect to the extraocular muscles and cerebral gray 
matter; B: Histopathologic examination shows a diffuse pattern of 
atypical lymphoid cells infiltrating normal glandular tissue consistent 
with the diagnosis of lymphoma (hematoxylin-eosin).
Figure 4 Lacrimal gland ACC in a 32 year-old woman  A: 
Contrast-enhanced T1-weighted coronal image shows heterogeneously 
enhancing mass with round-to-oval appearance; B: Gross photograph 
of the completely excised ACC shows a well-circumscribed mass with 
irregular margins; C: Histopathologic examination shows that nests 
and columns of tumor cells are arranged around gland-like spaces filled 
with basophilic and eosinophilic material, forming a “Swiss cheese” 
pattern consistent with a cribriform ACC (hematoxylin-eosin).
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Adenoid cystic carcinoma (12 cases, 12 lesions)  Total 
excisional biopsy via anterior orbitotomy was performed in 
11 cases and Kronlein orbitotomy in 1 case of ACC (Figure 
4B). Eight of 12 cases had the cribriform (Figure 4C) ACC 
while in 4 cases subtyping was not made. The 8th American 
Joint Committee on Cancer classifications (AJCC) of 12 
cases at initial diagnosis were as follows: T1aN0M0 (1 case), 
T2aN0M0 (7 cases), T2bN0M0 (1 case), T2cN0M0 (1 case), 
T3cN0M0 (1 case), and T4bN0M0 (1 case). Perineural 
invasion was found in 7 cases and microscopic tumor presence 
at surgical margins was detected in 6 cases at histopathologic 
examination. EBRT was administered in 6 cases (T1a and 
T2a), EBRT+chemotherapy in 2 (T2a), exenteration+EBRT 
in 1 (T2b), and bone removal exenteration+EBRT in 2 (T3c 
and T4b). The EBRT dose was 55-60 Gy. In one case with 
T2c ACC, additional treatment could not be performed after 
surgery due to the patient’s refusal of treatment. Recurrence 
in 2 cases was treated with exenteration in 1 case (T2a) and 
EBRT+chemotherapy in the other case (T1a). Eight cases 
(66.7%) with lesser AJCC stages (≤T2a)±tumor negative 
margins were treated with eye-sparing therapy (excisional 
biopsy+EBRT±chemotherapy) initially while 3 cases (25.0%) 
with more advanced tumors (≥T2b)+positive surgical 
margins were treated with exenteration+EBRT. Four of 8 
cases receiving eye-sparing surgery initially and 2 of 3 cases 
receiving exenteration developed metastasis. At a mean follow-
up of 55.5 (range: 3-159)mo, 3 of 3 cases ≤21 years of age and 
4 of 9 cases >21y were alive, 5 had expired.
Carcinoma ex pleomorphic adenoma (2 cases, 2 lesions) 
After diagnosis was established using anterior orbitotomy, both 
cases with Ca-ex-PA eventually underwent exenteration and 
EBRT (55-60 Gy). The time to development of Ca-ex-PA after 
incomplete excision of PA was 20 and 23y respectively in our 
2 cases.
Adenocarcinoma (1 case, 1 lesion)  This case was diagnosed 
with adenocarcinoma at a remote destination and managed 
with exenteration and EBRT (55 Gy) at our institution. 
Cavernous hemangioma (1 case, 1 lesion)  Total excisional 
biopsy via anterior orbitotomy was performed in the case with 
cavernous hemangioma. 
Dermoid cyst (1 case, 1 lesion)  The case with dermoid cyst 
was managed with total excision via anterior orbitotomy.
Leukemic infiltration (1 case, 1 lesion)  The case with 
leukemia was a 41 year-old woman who had previously 
diagnosed acute myeloid leukemia and underwent incisional 
biopsy via anterior orbitotomy for the lacrimal gland lesion 
that proved to be leukemic infiltration.
DISCUSSION
LGTs usually occur unilaterally and reflect a variety of 
underlying etiologic factors. A minority of cases demonstrate 
bilateral involvement at presentation, constituting a different 
clinical spectrum compared to unilateral presentations[8]. Tang 
et al[8] studied 97 patients with bilateral lacrimal gland disease 
and found that the most common diagnoses were idiopathic 
dacryoadenitis (30%), sarcoidosis (20%), lacrimal gland 
prolapse (15%), and lymphoma (11%). In our study, bilateral 
lacrimal gland involvement was found in 7 cases. Six of 7 
cases had dacryoadenitis and 1 had dacryops.
The most frequent LGT was idiopathic orbital inflammation 
(IOI) in our series accounting for 46 (46.5%) tumors followed 
by PA 14 (14.1%), ACC 12 (12.1%), granulomatous inflammation 
10 (10.1%), lymphoma 5 (5.0%), BRLH 3 (3.0%), dacryops 3 
(3.0%), Ca-ex-PA 2 (2.0%), adenocarcinoma 1 (1.0%), dermoid 
cyst 1 (1.0%), cavernous hemangioma 1 (1.0%), and leukemic 
infiltration 1 (1.0%). Our findings with respect to the frequency 
of orbital lesions are in accordance with other previous major 
publications[2,4-5].
LGTs may be found in patients of all ages, but are primarily 
encountered in middle-aged adults. Our series reflects the 
same tendency (Tables 1, 2). In our series, the cases with 
dacryoadenitis presented at a mean age of 35y, those with PA at 
a mean age of 42y and carcinomas at a mean age of 44y. There 
is a bimodal age distribution for ACC and ACC can also occur 
in younger patients. There were 3 cases of ACC aged less than 
21y in our series. On the other hand, lymphomas affected more 
elderly patients with a mean age of 69.
Patient history and clinical features are important in differentiating 
LGTs from each other (Table 2)[9]. Cases with acute dacryoadenitis 
usually presented with inflammatory signs including pain, 
eyelid edema, and conjunctival hyperemia. On the other hand, 
chronic dacryoadenitis cases presented with salient features 
including an upper eyelid mass and mild pain/discomfort. 
In our series, there were only 2 patients with dacryoadenitis 
presenting with pain. This low frequency may be attributable 
to the retrospective nature of our study and mild pain being 
an easily overlooked/missed symptom. Lymphoproliferative 
lesions were not usually associated with inflammatory signs. 
In our series, cases with PAs usually presented with >6mo 
duration of symptoms and no pain. Lacrimal gland carcinoma 
cases, on the other hand, presented with <6mo duration of 
symptoms and pain (Table 2). Orbital imaging (CT and MRI) 
is necessary to assist in the differentiation of LGTs[10]. Cases 
with dacryoadenitis and lymphoproliferative lesions usually 
presented with ill-defined oblong masses that molded to the 
shape of the globe and bone on CT and MRI. PAs usually 
displayed well-defined round-to-oval configuration sometimes 
with bone expansion. While early-caught carcinomas also 
had similar imaging findings to PAs, more aggressive or 
long-standing carcinomas displayed an ill-defined molded 
configuration to the lateral orbital bone similar to inflammatory 
and lymphoproliferative lesions. However, unlike inflammatory 
and lymphoproliferative lesions, carcinomas may cause bone 
destruction.
Lacrimal gland tumors
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Inflammatory lesions can be divided into two groups including 
non-granulomatous and granulomatous. In our study, non-
granulomatous lesions were present in approximately 80% 
of cases, and granulomatous lesions in the remaining 20% of 
cases, consistent with the reports of Shields et al[7] and von 
Holstein et al[1]. Non-granulomatous orbital inflammation 
consists mostly of IOI where no identifiable cause for 
inflammation can be found but there may be a few cases 
associated with vasculitis, infections, and other causes. 
Recently, taking a generous biopsy or debulking the lacrimal 
gland has been suggested as a means to improve the success 
rate of subsequent corticosteroid treatment[11]. In our series, 13 
cases had subtotal/total excision of the lacrimal gland in line 
with these observations. High dose systemic corticosteroids 
(1 mg/kg·d oral prednisolone) with a slow taper in the range 
of 5-10 mg per week, is the generally accepted standard 
treatment for dacryoadenitis[12]. However, response rate to 
corticosteroids is variable and ranges from 55% to 79%[13]. 
Methotrexate, azathioprine, cyclophosphamide, cyclosporine, 
rituximab, infliximab, and EBRT (20-30 Gy) may be added 
to the treatment in unresponsive or recurrent disease[14-15]. 
In our study, 8 of 50 (16.0%) cases with lacrimal gland 
inflammatory lesions required additional treatments besides 
oral corticosteroids.
Orbital lymphoproliferative lesions are the other common 
cause of non-epithelial tumors of the lacrimal gland. The 
distribution of lymphoma subtypes in our study confirms 
that ENMZL is the most frequent lymphoma subtype of the 
lacrimal gland (4 of 5 cases). In our study, all cases with 
ENMZL, except for the case who died from nontumor-
related cause, were alive at last follow-up, suggesting a good 
prognosis for ENMZL. If OAL is limited to the orbital and 
adnexal structures, incisional/excisional biopsy followed by 
EBRT is considered the treatment of choice. Furthermore, 
Mohammad and Kroosh[16] reported that small lacrimal gland 
lymphomas can be sufficiently treated by surgical excision 
alone and local control of disease is 100% at 5y. This was 
the case in one of our patients who was treated with surgical 
excision alone. EBRT is effective in 97% of OAL in terms of 
local tumor control. While conventional doses of 30-40 Gy 
produce excellent local control, there has been recent evidence 
that 2 Gy×2 (boom-boom treatment) may be sufficient to 
control the orbital disease with a high response rate of 96%[17].
PA is the most common benign tumor of the lacrimal gland, 
constituting 65% of all epithelial tumors. It usually occurs in 
patients between 30-40 years of age, but has been reported in 
children as young as 6 years old[18]. The youngest patient in 
our series was 16 years old. Complete excision of the tumor 
within its pseudocapsule via orbitotomy is recommended 
for treatment. Recurrence may occur if satellite nodules are 
not excised or the primary lesion is incompletely excised. 
Furthermore, it has been suggested that there is a significant 
risk of malignant transformation (about 10%) associated with 
long-standing PA that has never been excised or incompletely 
resected recurrent PA[19]. 
There may a spectrum of lesions including dacryoadenitis, 
lymphoma, and ACC simulating PA radiologically[20]. Recently, 
preoperative incisional biopsy and subsequent excision of 
lacrimal gland and biopsy track has been recommended as a 
more appropriate management option for PAs if there is doubt 
about diagnosis[20-21]. There is currently no robust evidence 
suggesting that prior incisional biopsy increases the risk of 
recurrence in PA. 
ACC is the most common malignant epithelial tumor of the 
lacrimal gland. Histopathologic types include cribriform, 
tubular, and solid (basaloid) pattern. The prognosis of ACC 
is associated with age, negative surgical margin, grade of 
perineural invasion, tumor histopathology, and tumor size[22]. 
Tellado et al[23] showed that patients younger than 19y tended 
to have low-grade tumors of non-basaloid type and therefore 
the rates of local control and survival were better than in 
adults. In our series, 3 of 3 cases ≤21 years of age were alive 
compared with 4 of 9 cases >21 years of age, reflecting the 
same tendency with the previously published literature. 
Perineural invasion is present in approximately 85% of cases 
with ACC. Perineural invasion demonstrates strong correlation 
with local tumor recurrence and skull base invasion. 
Histopathologically, the cribriform type has the best prognosis 
whereas the basaloid type has the worst prognosis[24].
Depending on the AJCC stage of ACC, an eye-sparing 
treatment approach may be attempted[25]. In our series, 8 cases 
with lesser AJCC stages (≤T2a) ± tumor negative margins were 
treated with eye-sparing surgery initially compared to 3 more 
advanced cases (≥T2b) with positive surgical margins treated 
with exenteration. EBRT was used in all cases. Regardless 
of the treatment approach, ACC is a locally invasive tumor 
and metastasis occurs frequently, with significant resultant 
mortality. In advanced tumors with extensive spread to soft 
tissues and bone marrow, exenteration±orbitectomy and 
EBRT are still the mainstays of treatment, although this kind 
of mutilating surgery may not positively affect long-term 
survival. 
Ca-ex-PA is the second most common primary epithelial 
malignancy of the lacrimal gland. It may occur de novo or 
may originate from malignant transformation of a primary 
or recurrent PA with sudden rapid enlargement. The 
carcinomatous component of Ca-ex-PA may show a variety of 
morphologies; however, adenocarcinoma, mucoepidermoid 
carcinoma, and ACC are more common[26]. In our study, there 
were 2 cases of adenocarcinoma ex PA which developed 20 
and 23y after incomplete excision of the primary PAs.
Lacrimal gland adenocarcinoma is a rare malignancy and 
usually occurs in an older population compared to ACC[27]. 
Adenocarcinoma has a propensity to metastasize earlier than 
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ACC and is associated with a shorter patient survival than 
ACC. In lacrimal gland adenocarcinomas, exenteration and 
EBRT are the recommended methods for treatment[27-28].
In summary, LGTs represent a wide variety of conditions. 
Fortunately, 79% are benign and can be managed with surgical 
excision or corticosteroids. The remaining 21% of tumors 
that are malignant comprise ACC, lymphoma, Ca-ex-PA, 
and adenocarcinoma. Some of the malignant tumors can be 
challenging to manage with a significant mortality rate.
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